RVP vs UTMD vs NVCR vs MMSI vs BDX

For growth investors, Merit Medical Systems, Inc.

(MMSI) is the stronger pick with 11. 7% revenue growth year-over-year, versus -24. 2% for Retractable Technologies, Inc. (RVP). Utah Medical Products, Inc. (UTMD) offers the better valuation at 18. 8x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Utah Medical Products, Inc.

(UTMD) is the cheapest at 18. 8x versus Merit Medical Systems, Inc. at 28. 8x. On forward P/E, Utah Medical Products, Inc. is actually cheaper at 10. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 72x versus Utah Medical Products, Inc. 's 3. 03x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +10.

9%, compared to -92. 6% for Retractable Technologies, Inc. (RVP). Over 10 years, the gap is even starker: MMSI returned +209. 3% versus RVP's -70. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Utah Medical Products, Inc.

(UTMD) is the lower-risk stock at 0. 55β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 287% more volatile than UTMD relative to the S&P 500. On balance sheet safety, Utah Medical Products, Inc. (UTMD) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Merit Medical Systems, Inc.

(MMSI) is pulling ahead at 11. 7% versus -24. 2% for Retractable Technologies, Inc. (RVP). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -66. 7% for Retractable Technologies, Inc.. Over a 3-year CAGR, MMSI leads at 9. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Utah Medical Products, Inc.

(UTMD) is the more profitable company, earning 29. 3% net margin versus -36. 0% for Retractable Technologies, Inc. — meaning it keeps 29. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTMD leads at 29. 6% versus -63. 9% for RVP. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 72x versus Utah Medical Products, Inc. 's 3. 03x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Utah Medical Products, Inc. (UTMD) trades at 10. 4x forward P/E versus 15. 1x for Merit Medical Systems, Inc. — 4. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 87. 3% to $33. 50.

In this comparison, BDX (2.

8% yield), UTMD (1. 9% yield), RVP (1. 1% yield) pay a dividend. NVCR, MMSI do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Utah Medical Products, Inc.

(UTMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 55), 1. 9% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UTMD: +19. 0%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

RVP, UTMD, BDX pay a dividend while NVCR, MMSI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.